G. Shankar

发表

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

M. Socinski, F. Cappuzzo, T. Mok, 2022, Journal for ImmunoTherapy of Cancer.

IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

M. Socinski, D. Moro-Sibilot, C. Barone, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.

J. Ware, J. Spoerke, J. Schellens, 2017, The oncologist.

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.

M. Socinski, F. Cappuzzo, T. Mok, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

P. Jänne, S. Gettinger, F. Shepherd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

G. Hampton, P. Hegde, I. Wistuba, 2018, Proceedings of the National Academy of Sciences.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

H. Groen, J. Ware, K. Morrissey, 2017, European Journal of Cancer.

A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).

J. Ware, J. Soria, R. Brachmann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

G. Hampton, P. Hegde, G. Frampton, 2017 .

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

M. Socinski, F. Cappuzzo, T. Mok, 2019, The Lancet. Respiratory medicine.

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations

M. Socinski, V. Papadimitrakopoulou, M. Mccleland, 2019, Expert review of respiratory medicine.

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

David S. Shames, Matthew D. Hellmann, Garrett M. Frampton, 2016 .

1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations

M. Socinski, T. Mok, D. Shames, 2020 .

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC.

M. Socinski, D. Moro-Sibilot, C. Barone, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab

V. Velcheti, J. Mazières, J. Goldschmidt, 2018, Journal of Thoracic Oncology.

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.

M. Socinski, T. Mok, D. Moro-Sibilot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations

M. Socinski, T. Mok, F. Barlesi, 2020 .

Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups

M. Socinski, F. Cappuzzo, T. Mok, 2020 .

IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)

M. Socinski, V. Papadimitrakopoulou, M. Nishio, 2020, Pneumologie.